Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 175% above its 5-year average of 36.36%, near the high end of its 5-year range (0.00%–100.00%).
As of the fiscal period ended Wednesday, December 31, 2025. 100.00% above its 12-month average of 50.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2025-12-31): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
50.00%
GROSS MARGIN AVG 3Y
37.50%
GROSS MARGIN AVG 5Y
36.36%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+166.67%
CURRENT VS 5Y AVG
+175.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.74%
median of 628 covered companies
CURRENT VS SECTOR MEDIAN
+139.55%
vs the sector median at left
Gelteq Limited Ordinary Shares
Market Cap
$5.17M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
37.50%
5Y Avg
36.36%
Market Cap
$5.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.27M
Gross Margin
48.63%
TTM Avg
44.74%
3Y Avg
40.32%
5Y Avg
43.55%
Market Cap
$5.01M
Gross Margin
77.68%
TTM Avg
77.66%
3Y Avg
77.69%
5Y Avg
77.69%
Market Cap
$4.83M
Gross Margin
19.34%
TTM Avg
59.23%
3Y Avg
54.62%
5Y Avg
36.41%
Market Cap
$5.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.17M | 100.00% | 50.00% | 37.50% | 36.36% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | 48.63% | 44.74% | 40.32% | 43.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | 77.68% | 77.66% | 77.69% | 77.69% |
| Imunon, Inc. (IMNN)vs › | $4.99M | 0.00% | 0.00% | 25.00% | 50.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.83M | 19.34% | 59.23% | 54.62% | 36.41% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | 100.00% | 99.28% | 89.13% | 81.38% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 0.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 0.00% |
| 2021-06-30 | 0.00% |
